Granzyme B Antibody | C-Terminal Antibody

	Catalog No	Formulation	Size	Price (USD)
	R20456-0.1ML	Antibody in PBS with 50% glycerol, 1% BSA and 0.09% sodium azide	100 ul	439
Formulation

Granzyme B Antibody Human Lung Squamous Cell Carcinoma IHC. Immunohistochemical staining of FFPE human lung squamous cell carcinoma tissue using Granzyme B Antibody at a 1:200 dilution. An HRP-conjugated secondary antibody with DAB substrate was used for detection. Granzyme B Antibody, recognizing GZMB, demonstrates granular cytoplasmic staining in scattered infiltrating cytotoxic lymphocytes within the tumor microenvironment, consistent with granzyme B expression in activated cytotoxic T lymphocytes and natural killer cells.

Granzyme B Antibody Human Tonsil IHC. Immunohistochemical staining of FFPE human tonsil tissue using Granzyme B Antibody at a 1:200 dilution. An HRP-conjugated secondary antibody with DAB substrate was used for detection. Granzyme B Antibody, recognizing GZMB, demonstrates granular cytoplasmic staining in scattered lymphocytes within the tonsillar lymphoid tissue, consistent with granzyme B expression in activated cytotoxic T lymphocytes and natural killer cells.

›

Granzyme B Antibody Human Lung Squamous Cell Carcinoma IHC. Immunohistochemical staining of FFPE human lung squamous cell carcinoma tissue using Granzyme B Antibody at a 1:200 dilution. An HRP-conjugated secondary antibody with DAB substrate was used for detection. Granzyme B Antibody, recognizing GZMB, demonstrates granular cytoplasmic staining in scattered infiltrating cytotoxic lymphocytes within the tumor microenvironment, consistent with granzyme B expression in activated cytotoxic T lymphocytes and natural killer cells.

Granzyme B Antibody Human Tonsil IHC. Immunohistochemical staining of FFPE human tonsil tissue using Granzyme B Antibody at a 1:200 dilution. An HRP-conjugated secondary antibody with DAB substrate was used for detection. Granzyme B Antibody, recognizing GZMB, demonstrates granular cytoplasmic staining in scattered lymphocytes within the tonsillar lymphoid tissue, consistent with granzyme B expression in activated cytotoxic T lymphocytes and natural killer cells.

Availability	1-3 business days
Species Reactivity	Human
Format	Purified
Host	Rabbit
Clonality	Recombinant Rabbit Monoclonal
Isotype	Rabbit IgG
Clone Name	RM441
Purity	Protein A purified from animal origin-free supernatant
UniProt	P10144
Localization	Cytoplasmic
Applications	Immunohistochemistry (FFPE) : 1:100-1:200
Limitations	This Granzyme B Antibody / C-Terminal Antibody is available for research use only.
	Review this product on BioCompare and get a $20 Amazon gift card

Description

Granzyme B Antibody recognizes granzyme B (GZMB), a cytotoxic serine protease that serves as one of the principal effector molecules released by activated CD8-positive cytotoxic T lymphocytes and natural killer (NK) cells during cell-mediated immune responses. Following immune synapse formation, granzyme B enters target cells through perforin-generated pores and initiates apoptosis by activating caspases and cleaving multiple intracellular substrates, including BID and PARP. This highly regulated mechanism is essential for eliminating virus-infected, transformed, and malignant cells, making Granzyme B Antibody an important research tool for investigating immune surveillance, host defense, and cytotoxic lymphocyte function.

Granzyme B expression is largely restricted to activated cytotoxic immune cells and is therefore widely used as a functional biomarker of immune activation rather than simply a marker of lymphocyte lineage. Increased GZMB expression has been associated with effective antitumor immunity, antiviral responses, transplant rejection, autoimmune disease, and chronic inflammatory disorders. Consequently, Granzyme B Antibody is frequently used to identify activated cytotoxic T cells and NK cells within tissues and to evaluate immune responses in oncology, infectious disease, and immunology research.

This recombinant rabbit monoclonal Granzyme B Antibody (clone RM441) was generated against a peptide corresponding to the C-terminal region of granzyme B. Because the C-terminus is retained following proteolytic maturation of the protein, antibodies directed against this region are expected to recognize both precursor and mature forms of GZMB while maintaining high target specificity. Recombinant antibody technology further provides excellent lot-to-lot consistency, long-term supply reliability, and reproducible performance across research applications.

For additional information about granzyme B biology, protein microarray-validated antibodies, validated applications, and related products, learn more about our Granzyme B Antibody, a Cytotoxic Lymphocyte Marker Antibody for investigating immune cell activation, cell-mediated cytotoxicity, tumor immunity, and natural killer cell function.

Learn more about our Granzyme B Antibody, a Cytotoxic Lymphocyte Marker Antibody for investigating immune cell activation, cell-mediated cytotoxicity, tumor immunity, and natural killer cell function.

Application Notes

The stated application concentrations are suggested starting points. Titration of the Granzyme B Antibody / C-Terminal Antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Immunogen

A peptide corresponding to the C-terminus of Granzyme B was used as the immunogen for the recombinant Granzyme B antibody.

Storage

Store the recombinant Granzyme B antibody at -20oC.

Alternate Names

GZMB Antibody, C-Terminal Granzyme B Antibody, CTLA1 Antibody, Serine Protease Granzyme B Antibody, Granzyme-2 Antibody, Recombinant Rabbit Granzyme B Antibody

Related Products

1. View all Granzyme B antibodies

Granzyme B Antibody / C-Terminal Antibody [clone RM441] (R20456)

Description

Application Notes

Immunogen

Storage

Alternate Names

Related Products

Area of Research

Product Type

Protocols

Contact Us

NSJ Bioreagents